By contrast, several other studies have reported a stronger association between IgG anti-B2GPI and clinical manifestations of APS compared with IgM anti-B2GPI which has cast considerable doubt on the role of IgM anti-B2GPI in the first-line assessment of APS. This evidence concerns the gene APOH and autoimmune polyendocrinopathy.